MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

In 2017, nearly half of MSF's patients in Serbia were under 18; almost all of them were refugees and asylum-seekers who were traveling unaccompanied or became separated from their parents. Minors are supposed to be protected by the system, but many of these young people report violent abuse by European Union border authorities and police.

With winter starting to factor into people's thoughts, prospects seem grim for many of the migrants living in the notorious "Jungle" camp in Calais, in northern France. The French government has vowed to shut the camp down once and for all. Another barrier—a 13-foot-high, half-mile-long wall—appears set to go up. And just this week, Calais residents held demonstrations and set up roadblocks demanding that the camp be razed.

Even though assistance to the camp appears to have thinned, people are still making their way there.

New York/Ise-Shima/Geneva—As the leaders of the G7 countries gather in Ise-Shima, Japan over the next two days, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to make a bold commitment to prioritize a better global response to public health emergencies and to take action to encourage the research and development (R&D) and affordable pricing of critical medicines.

The earthquakes that ratted southwestern Japan last week injured around 1,100 people in Kumamoto and Oita prefectures and led to the deaths of another 58. Roughly 103,000 people remained displaced in Kumamoto and around 600 in Oita, and the authorities are still searching for people who are unaccounted for as well. What's more, due to heavy rains and the subsequent risk of landslides, some 240,000 people have been advised to evacuate 19 cities, towns and villages in Kumamoto and Oita.

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

Stories include: MSF teams treating wounded people in Misrata, Libya; the need for mental healthcare to survivors of Japan's tsunami; the new treatment target set by the United Nations to reach 15 million people living with HIV by 2015; and amendments to French law that suspend the ability of foreigners to get a temporary right of residence, which could create a public health risk.

Pages

In 2017, nearly half of MSF's patients in Serbia were under 18; almost all of them were refugees and asylum-seekers who were traveling unaccompanied or became separated from their parents. Minors are supposed to be protected by the system, but many of these young people report violent abuse by European Union border authorities and police.

With winter starting to factor into people's thoughts, prospects seem grim for many of the migrants living in the notorious "Jungle" camp in Calais, in northern France. The French government has vowed to shut the camp down once and for all. Another barrier—a 13-foot-high, half-mile-long wall—appears set to go up. And just this week, Calais residents held demonstrations and set up roadblocks demanding that the camp be razed.

Even though assistance to the camp appears to have thinned, people are still making their way there.

New York/Ise-Shima/Geneva—As the leaders of the G7 countries gather in Ise-Shima, Japan over the next two days, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to make a bold commitment to prioritize a better global response to public health emergencies and to take action to encourage the research and development (R&D) and affordable pricing of critical medicines.

The earthquakes that ratted southwestern Japan last week injured around 1,100 people in Kumamoto and Oita prefectures and led to the deaths of another 58. Roughly 103,000 people remained displaced in Kumamoto and around 600 in Oita, and the authorities are still searching for people who are unaccounted for as well. What's more, due to heavy rains and the subsequent risk of landslides, some 240,000 people have been advised to evacuate 19 cities, towns and villages in Kumamoto and Oita.

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

Stories include: MSF teams treating wounded people in Misrata, Libya; the need for mental healthcare to survivors of Japan's tsunami; the new treatment target set by the United Nations to reach 15 million people living with HIV by 2015; and amendments to French law that suspend the ability of foreigners to get a temporary right of residence, which could create a public health risk.